絞り込み

16603

広告

キンギョの「設計図」解読 (デイリースポーツ)

キンギョのゲノム(全遺伝情報)解読に初めて成功したと、大阪大などのチームが26日付の米科学誌電子版に発表した。ゲノムは生物の設計図ともいわれ、さまざまな形態を持...

  1. 家畜ふん尿:お得に燃料 阪大開発 秋に北...
  2. 科学の森:続く黒潮大蛇行、影響は 12年...
  3. 今どきサイエンス:文化としての科学=鴨志...
  4. 深海アイドル図鑑:/97 宝石サンゴ (...

ニュース一覧

Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy.

著者 Leder BZ
JBMR Plus.2018 Mar ; 2(2):62-68.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (41view , 0users)

Full Text Sources

As osteoporosis therapy options have expanded, and clinical guidelines have begun to embrace the concept of limited treatment courses and "drug holidays," the choices that physicians must make when initiating, electing to continue, or switching therapies have become more complex. As a result, one of the fundamental issues that must be carefully considered is whether, when, and in what sequence anabolic therapies should be utilized. This review evaluates the current evidence supporting the optimal sequence for the use of anabolic and antiresorptive drugs and assesses the expanding number of clinical trials favoring the initial use of anabolic therapy followed by an antiresorptive agent. This review also explores the evidence suggesting that the effectiveness of anabolic medications are diminished when used in patients that have been previously treated with specific antiresorptive drugs for prolonged periods. Finally, the recent advances in designing combination antiresorptive/anabolic treatment approaches are detailed, with a focus on combined denosumab/teriparatide regimens, which appear to provide the most substantial and clinically relevant skeletal benefits to patients with established osteoporosis. © 2018 The Authors. JBMR Plus is published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.
PMID: 30283892 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード